MTR CELEBRATES 100 YEARS WITH WORLD'S LONGEST DOSA MEASURING 123 FEET -ENTERS GUINNESS WORLD RECORDS.

Celebrating 100 years MTR style-MTR Foods announced that they are now the new GUINNESS WORLD RECORDS Title holder for the Longest Dosa in partnership with Lorman Kitchen Equipments. MTR's signature Red Rice Batter was used to prepare this Longest Dosa at its Bommasandra Factory.The record was created by a team of 75 Chefs,comprising of both seasoned experts & budding culinary talent,under the guidance of MTR's Cuisine Centre of Excellence.

Mr.Sunay Bhasin,CEO of MTR said,"Dosa has been a part of MTR's legacy from the very beginning and it continues to be one of the most loved products of MTR even today.From a humble south Indian Dish,it is now recognised & loved worldwide.The longest Dosa world record is a celebration of our bond with our consumers and their favourite dish".

Mr.Chandra Mouli,MD.Lorman Kitchen Equipment Pvt.Ltd., added," World's longest dosa is being cooked on a specially built induction stove,the biggest ever from Lorman.We are proud to be associated with MTR on this remarkable event."

About MTR: A popular household name MTR is synonymous with delicious Indian food is an easy-to-use packaged format.With a diverse portfolio including many iconic products like sambar powder,Puliogare,Rava Idli,Gulab Jamun mix,Badam drink mix which are house hold names today.MTR unifies India tastefully-making the home maker the 'Hero'. MTR Pvt.Ltd., is a subsidiary of Norwegian conglomerate Orkla. Orkla India is a collection of leading local Indian food
 brands.It owns iconic heritage brands -MTR,Rasoi Magic & Eastern.

ROCHE LAUNCHES "VABYSMO"(faricimab),THE FIRST AND ONLY BISPECIFIC MONOCLONAL ANTIBODY FOR THE EYE,TO TREAT TWO LEADING CAUSES OF VISION LOSS.

Roche pharma India marked its foray into the opthalmology space by launching VABYSMO"(faricimab)for the treatment of neovascular or wet age related macular degeneration (nAMD)and diabetic macular edema(DME).Neovascular AMD and DME are leading causes of vision loss worldwide."Vabysmo"is the first and only dual-pathway-inhibitor that uniquely targets and inhibits two disease pathways linked to a number of vision threatening retinal conditions.Vabysmo is a single molecule designed to provide the benefits of two medicines in one.

"VABYSMO" has the potential to transform the existing standard of Care (SoC) as the burden associated with currently available treatment options for nAMD & DME such as frequent eye injections (typically required every one to two months)and physician visits can lead to under treatment and less than optimal vision outcomes.

Commenting on the launch,Mr.V.Simpson Emmanuel,CEO & Managing Director,Roche Pharma India,"We believe more should be done to meet the needs of people living with retinal conditions & to preserve sight.While there is strong awareness and action for cataract and other frontal eye-disorders,retinal conditions are often diagnosed late or neglected leading to vision loss.The Launch of "VABYSMO" marks our entry into the opthalmology space in India,underscoring our commitment to bring the best-in-class innovations to the country.With fewer eye injections over time,while also improving and maintaining vision & anatomy,"VABYSMO" offers a more convenient & effective treatment schedule for patients,their caregivers and healthcare systems".

Dr.Chaitra Jayadev,Head of Vitreoretina Services at Narayana Nethralaya Eye Institute,Said, "As retina specialists, we see this as a game changer in our field,offering new hope and possibilities for our patients battling these complex retinal diseases'.

"VABYSMO" (faricimab) was first approved by the USFDA in January,2022.It is today available in across 90+countries and more than 2 million doses have been administered till date".

It was said during the discussions, that Diabetes is one of the triggering factors for Retinal Disorders.

HELIOS MUTUAL FUND LAUNCHES " HELIOS BALANCED ADVANTAGE FUND" (BAF).

Helios Mutual Fund announced the launch of Helios Balanced Advantage Fund (BAF),an open ended dynamic asset allocation fund.This NFO will open for subscription on March,11,2024 & Close on March 20,2024.This fund aims to capitalize on the potential upside of eauities while attempting to limit the downside through dynamic portfolio management.This will be done by investing in equity & equity related instruments and active use of debt,money market instruments & derivatives.The equity portfolio will be built on basis "Helio's Elimination Investing" philosophy-based on eight fundamental  screening factors that have repeatedly proven to be effective in weeding out poor performers,gravitating towards winners,and creating a sustainable outperformance profile.

The investment strategy will be to normally maintain gross equity and equity related exposure between 65% -100% and the net equity exposure between 30% to 80%.Various derivative strategies would be used for hedging against market headwinds. Addressing the media Mr. Sameer Arora,the main Founder &Fund Manager  of Helios Capital said," Why the investor should invest in Helios Balanced Advantage Fund: Mr.Samir Arora has an investing experience of 29 years.

   Growth Potential with balanced allocation.

   Attempts to limit downside risk by hedging,tweaking debt.

  Endeavors to allocate =/> 65% into equities,which will provide the scheme with equity fund taxation.

  Units can be redeemed on any Business Day at NAV based price.

  Risk mitigation & rigorous screening.

  Fund Managers with more than 25 years of combined Experience .

Consistency & Disciplined investing.

The Minimum Application amount will be Rs.5000/- & in multiples of Re.1 thereafter.

Please Note: Mutual Fund investments are subject to market risks,read all scheme related documents carefully.

                                                     

                                                 *